Back to Search Start Over

Thrombosis and hemorrhage experienced by hospitalized children with SARS-CoV-2 infection or MIS-C: Results of the PICNIC registry.

Authors :
Tehseen S
Williams S
Robinson J
Morris SK
Bitnun A
Gill P
Tal TE
Yeh A
Yea C
Ulloa-Gutierrez R
Brenes-Chacon H
Yock-Corrales A
Ivankovich-Escoto G
Soriano-Fallas A
Papenburg J
Lefebvre MA
Scuccimarri R
Nateghian A
Aski BH
Dwilow R
Bullard J
Cooke S
Restivo L
Lopez A
Sadarangani M
Roberts A
Forbes M
Saux NL
Bowes J
Purewal R
Lautermilch J
Bayliss A
Wong JK
Leifso K
Foo C
Panetta L
Kakkar F
Piche D
Viel-Theriault I
Merckx J
Lieberman L
Source :
Pediatric blood & cancer [Pediatr Blood Cancer] 2022 Sep; Vol. 69 (9), pp. e29793. Date of Electronic Publication: 2022 Jun 11.
Publication Year :
2022

Abstract

Introduction: Coagulopathy and thrombosis associated with SARS-CoV-2 infection are well defined in hospitalized adults and leads to adverse outcomes. Pediatric studies are limited.<br />Methods: An international multicentered (n = 15) retrospective registry collected information on the clinical manifestations of SARS-CoV-2 and multisystem inflammatory syndrome (MIS-C) in hospitalized children from February 1, 2020 through May 31, 2021. This sub-study focused on coagulopathy. Study variables included patient demographics, comorbidities, clinical presentation, hospital course, laboratory parameters, management, and outcomes.<br />Results: Nine hundred eighty-five children were enrolled, of which 915 (93%) had clinical information available; 385 (42%) had symptomatic SARS-CoV-2 infection, 288 had MIS-C (31.4%), and 242 (26.4%) had SARS-CoV-2 identified incidentally. Ten children (1%) experienced thrombosis, 16 (1.7%) experienced hemorrhage, and two (0.2%) experienced both thrombosis and hemorrhage. Significantly prevalent prothrombotic comorbidities included congenital heart disease (p-value .007), respiratory support (p-value .006), central venous catheter (CVC) (p = .04) in children with primary SARS-CoV-2 and in those with MIS-C included respiratory support (p-value .03), obesity (p-value .002), and cytokine storm (p = .012). Comorbidities prevalent in children with hemorrhage included age >10 years (p = .04), CVC (p = .03) in children with primary SARS-CoV-2 infection and in those with MIS-C encompassed thrombocytopenia (p = .001) and cytokine storm (p = .02). Eleven patients died (1.2%), with no deaths attributed to thrombosis or hemorrhage.<br />Conclusion: Thrombosis and hemorrhage are uncommon events in children with SARS-CoV-2; largely experienced by those with pre-existing comorbidities. Understanding the complete spectrum of coagulopathy in children with SARS-CoV-2 infection requires ongoing research.<br /> (© 2022 Wiley Periodicals LLC.)

Details

Language :
English
ISSN :
1545-5017
Volume :
69
Issue :
9
Database :
MEDLINE
Journal :
Pediatric blood & cancer
Publication Type :
Academic Journal
Accession number :
35689507
Full Text :
https://doi.org/10.1002/pbc.29793